Ellipses Pharma widens its orbit
The biotech licenses a China-developed anti-B7-H3 ADC.
One Genmab Rybrevant challenge is rendered moot
GEN1286 looks dead, though MCLA-129 continues for now.
Two more in vivo Cars head for the clinic
New first-in-human study initiations feature yet more in vivo Car assets.
Licensing analysis: Takeda saves the day
The Japanese group’s $1.2bn deal with Innovent is by far the biggest of the fourth quarter.
ImmunityBio tries again in papillary bladder cancer
And the company says it won’t need to carry out another trial.
Epkinly fails its first confirmatory test
And that could affect the drug's third-line accelerated approval.
M&A analysis: bolt-ons for J&J and Bristol
The biggest oncology buy of the quarter concerned the prostate cancer player Halda.
